Dasatinib-Induced Pulmonary Arterial Hypertension |
| |
| Institution: | 1. Section of Respirology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;2. Division of Respirology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada;3. Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada;1. Cardiovascular Department, GVM Care and Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy;2. Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona, Ferrara, Italy |
| |
| Abstract: | A 73-year-old woman with chronic myeloid leukemia developed severe pulmonary arterial hypertension (PAH) and pleural effusions after treatment with dasatinib. During workup, partial anomalous pulmonary venous connection and a sinus venosus atrial septal defect were found; these anomalies may have predisposed her to developing this rare and life-threatening condition. Fortunately, her PAH was completely reversible by discontinuation of dasatinib. This case highlights dasatinib’s ability to cause PAH in patients predisposed to pulmonary vascular disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
